Log in
Enquire now
Resalis Therapeutics

Resalis Therapeutics

Resalis Therapeutics is developing first-in-class anti-miR compounds to address high unmet medical needs in liver diseases, metabolic disorders, and cancer using a multi-pathway approach.

OverviewStructured DataIssuesContributors

Contents

resalistherapeutics.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Technology
Technology
RNA-based and RNA-targeted therapeutics
RNA-based and RNA-targeted therapeutics
Biology
Biology
Biotechnology
Biotechnology
Location
Turin
Turin
0
CEO
‌
Eva Castagnetti
0
Pitchbook URL
pitchbook.com/profiles...470926-09
Email Address
Full Address
Via Nizza 52 10126, Torino, Italy0
Total Funding Amount (USD)
11,000,000
Latest Funding Round Date
February 22, 2023
Latest Funding Type
Seed
Seed
Country
Italy
Italy
0

Other attributes

Company Operating Status
Active0
Latest Funding Round Amount (USD)
11,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Resalis Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Become an Editor
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.